Will Using Semaglutide Increase Your Risk of Thyroid Cancer?
New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...
Medscape26d
Immune System the Missing Link in Blood Glucose Control?
Immune cells native to the intestines travel to the pancreas to stimulate glucagon production in pancreatic alpha cells, thereby contributing to the regulation of blood glucose levels, suggests a ...
Nature4y
G-Protein-Coupled Receptors, Pancreatic Islets, and Diabetes
In addition to impaired insulin secretion, type 2 diabetic patients also have elevated levels of glucagon, which worsens hyperglycemia by increasing glucose production by the liver. Type 2 ...
Nasdaq14d
OPKO & Entera Bio To Develop First Oral GLP-1/Glucagon Dual Agonist
(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic ...
PipelineReview.com8d
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
GUANGDONG, China and BAGSVAERD, Denmark I March 24, 2025 IThe United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) ...
Zawya8d
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose ... is mainly engaged in the research and development, production and ...